{"groups":[{"description":"Nivolumab 240 mg/body solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends","id":"FG000","title":"Nivolumab Arm"},{"description":"Docetaxel: Intravenously administered at a dose of 75 mg/m2 every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends\n\nOR\n\nPaclitaxel: Intravenously administered at a dose of 100 mg/m2 weekly for 6 weeks followed by 2-week drug holiday until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends","id":"FG001","title":"Active Comparator Arm （Docetaxel/Paclitaxel）"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"comment":"Included in intention-to-treat analysis for overall survival and progression-free survival","groupId":"FG000","numSubjects":"210"},{"comment":"Included in intention-to-treat analysis for overall survival and progression-free survival","groupId":"FG001","numSubjects":"209"}],"comment":"Enrolled and randomly assigned","type":"STARTED"},{"achievements":[{"comment":"Analysed for safety","groupId":"FG000","numSubjects":"209"},{"comment":"Analysed for safety","groupId":"FG001","numSubjects":"208"}],"comment":"Received assigned treatment of IMP","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}